Real‐world data prognostic model of overall survival in patients with advanced <scp>NSCLC</scp> receiving anti‐<scp>PD</scp>‐1/<scp>PD‐L1</scp> immune checkpoint inhibitors as second‐line monotherapy

Abstract

Based on baseline demographic and clinical factors from a real-world setting, this prognostic model was developed to discriminate the risk of death in patients with aNSCLC treated with checkpoint inhibitors as second-line monotherapy, and it performed well in the real-world data and clinical trial cohorts.